a RNA expression of SIRT1–7 in PBMCs from healthy controls and RA patients (n = 5–20). b SIRT5 gene expression in healthy volunteers (n = 29) and patients with RA (n = 38) or osteoarthritis (n = 17). Unpaired t-test, *P < 0.05, **P < 0.01, and ***P < 0.001. c SIRT5 mRNA levels in PBMCs and synovial tissues of AIA rats (day 30, n = 6). d SIRT5 protein expression in rat synovial tissues (day 30, n = 4). e Effect of SIRT5 expression in MTX- and SIRT5 inhibitor suramin-treated RASFs. f Effect of SIRT5 expression in proinflammatory cytokine-treated RASFs. g Production of proinflammatory cytokines in human CD14+CD16− monocytes with overexpression or h knockdown of SIRT5 in the presence or absence of suramin. *P < 0.05, **P < 0.01, and ***P < 0.001 vs untransfected controls. i The arthritic scores and j hind paw volumes of Ad-SIRT5 overexpression in AIA rats (n = 8–12). #P < 0.05 vs healthy ctrl; *P < 0.05 and **P < 0.01 vs Ad-EGFP vehicle ctrl. k Micro-CT radiographic images showing Ad-SIRT5 overexpression in AIA rats. l Histopathological sections (scale bar: 100 μm) and m immunofluorescence images (scale bar: 50 μm) showing synovial tissue from Ad-SIRT5-treated AIA rats. n Arthritic scores and o increased hind paw volumes of SIRT5+/+, SIRT5−/−, and SIRT5−/− + EP AIA rats. p Characterization of succinylation distribution in different tissues and q the hypersuccinylation of PKM2 in SIRT5+/+ and SIRT5−/− SD rats. r Detection of acetyl CoA and pyruvate in livers of SIRT5+/+, SIRT5−/−, and SIRT5−/− + EP rats. **P < 0.01 and ***P < 0.001, by one-way ANOVA. The data shown are the mean ± SEM.